Jubilant Pharmova shares in focus after USFDA issues five observations to its US-based unit

Share it

This transaction, aimed at bolstering Jubilant Biosys’ expertise in biologics and antibody-drug conjugates (ADC), and was contingent on the approval of the offer by Pierre Fabre.

Leave a Comment

Your email address will not be published. Required fields are marked *